These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27218484)

  • 1. Are depot as effective as oral antipsychotics on first-episode psychosis?
    Orus C; Aceituno D
    Medwave; 2016 May; 16 Suppl 2():e6447. PubMed ID: 27218484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
    Adams CE; Fenton MK; Quraishi S; David AS
    Br J Psychiatry; 2001 Oct; 179():290-9. PubMed ID: 11581108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia?
    Jiménez-Cornejo M; Munizaga G; Aceituno D
    Medwave; 2016 Dec; 16(Suppl5):e6614. PubMed ID: 27922589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.
    Francey SM; Nelson B; Thompson A; Parker AG; Kerr M; Macneil C; Fraser R; Hughes F; Crisp K; Harrigan S; Wood SJ; Berk M; McGorry PD
    Schizophr Res; 2010 Jun; 119(1-3):1-10. PubMed ID: 20347270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
    Patel MX; de Zoysa N; Bernadt M; David AS
    J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review.
    Salgueiro M; Segarra R
    Int Clin Psychopharmacol; 2019 Mar; 34(2):51-56. PubMed ID: 30540617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].
    Breit S; Hasler G
    Nervenarzt; 2016 Jul; 87(7):719-23. PubMed ID: 26597275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot antipsychotics in practice. Their rôle in schizophrenia and related psychoses.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-78. PubMed ID: 2881965
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex, ethnicity, and antipsychotic medication use in patients with psychosis.
    Arnold LM; Strakowski SM; Schwiers ML; Amicone J; Fleck DE; Corey KB; Farrow JE
    Schizophr Res; 2004 Feb; 66(2-3):169-75. PubMed ID: 15061250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge about antipsychotic long-acting injections: bridging that gap.
    Burns T
    Br J Psychiatry Suppl; 2009 Nov; 52():S5-6. PubMed ID: 19880917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.